Document 0904
 DOCN  M9620904
 TI    Evidence for an antiviral effect and interferon neutralizing capacity in
       human sera; variability and implications for HIV infection.
 DT    9602
 AU    Fall LS; Chams V; Le Coq H; Fouchard M; M'Bika JP; Gringeri A;
       Santagostino E; Bizzini B; Laboratoire de Physiologie Cellulaire,
       Universite Pierre et; Marie Curie, Paris, France.
 SO    Cell Mol Biol (Noisy-le-grand). 1995 May;41(3):409-16. Unique Identifier
       : AIDSLINE MED/96059402
 AB    The antiviral effect (AVE) and interferon neutralizing capacity (INC) of
       sera originating from either seronegative or HIV-infected individuals
       were determined. As a rule, sera from seropositive subjects exhibited
       higher AVE titers than sera from seronegative individuals. Similarly,
       the INC of sera from HIV-infected patients, was most often stronger than
       that of sera from seronegative individuals. Furthermore, sera from
       HIV-infected patients actively immunized with i-IFN alpha invariably
       expressed INC in response to treatment, which was not the case for sera
       from control unimmunized patients. All sera from HIV-infected patients
       were found by ELISA to contain antibodies specifically directed to IFN
       alpha.
 DE    Acquired Immunodeficiency Syndrome/*IMMUNOLOGY/VIROLOGY  Antibodies,
       Viral/*IMMUNOLOGY  Antibody Formation  Antiviral Agents/BLOOD
       Comparative Study  CD4 Lymphocyte Count  Enzyme-Linked Immunosorbent
       Assay  Female  Human  Immune Sera/*IMMUNOLOGY
       Interferon-alpha/BLOOD/*IMMUNOLOGY  Male  Neutralization Tests  Time
       Factors  Vaccination  Vaccines, Synthetic/IMMUNOLOGY  JOURNAL ARTICLE

       SOURCE: National Library of Medicine.  NOTICE: This material may be
       protected by Copyright Law (Title 17, U.S.Code).